CSL Reviews Non-Plasma Unit as Perreault Mulls Options

CSL Ltd., the world’s second-biggest maker of blood-derived therapies, is taking a hard look at its non-plasma businesses as incoming head Paul Perreault tries to assess their growth prospects.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.